ADMA Biologics is trading at $13.36, up 27.48%, in after-hours trading after Q3 revenue beat expectations. - The price followed the November 4, 2026 regular-session close. - Revenue was $141.1 million, beating expectations of $139.8 million. Asceniv revenue rose 31% year over year to $124.7 million. - Gross margin expanded to 71% from 56% a year earlier. The company had scheduled its earnings release after the market close, making the results a direct, timely catalyst.